Cargando…
AZD8797 is an allosteric non-competitive modulator of the human CX3CR1 receptor
The chemokine receptor CX(3)CR1 has been implicated as an attractive therapeutic target in several diseases, including atherosclerosis and diabetes. However, there has been a lack of non-peptide CX(3)CR1 inhibitors to substantiate these findings. A selective small-molecule inhibitor of CX(3)CR1, AZD...
Autores principales: | Cederblad, Linda, Rosengren, Birgitta, Ryberg, Erik, Hermansson, Nils-Olov |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764977/ https://www.ncbi.nlm.nih.gov/pubmed/26656484 http://dx.doi.org/10.1042/BJ20150520 |
Ejemplares similares
-
A novel CX3CR1 inhibitor AZD8797 facilitates early recovery of rat acute spinal cord injury by inhibiting inflammation and apoptosis
por: Chen, Guozhao, et al.
Publicado: (2020) -
Modulating neurotoxicity through CX3CL1/CX3CR1 signaling
por: Limatola, Cristina, et al.
Publicado: (2014) -
Role of the CX3C chemokine receptor CX3CR1 in the pathogenesis of atherosclerosis after aortic transplantation
por: Rowinska, Zuzanna, et al.
Publicado: (2017) -
CX3CR1 in multiple sclerosis
por: Rivest, Serge
Publicado: (2015) -
Role of CX(3)CR1 Receptor in Monocyte/Macrophage Driven Neovascularization
por: Kumar, Arun H. S., et al.
Publicado: (2013)